Teva Pharmaceutical Industries Ltd, a global pharmaceutical company major has recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved injection of COPAXONE® as for treating relapses in multiple sclerosis (MS).
The once per day 20 mg injection of COPAXONE was approved to be used as prophylaxis. The active ingredient of COPAXONE is acetate salts of synthetic polypeptides, which contains amino acids such as L-glutamic acid, L-alanine, L-lysine and L-tyrosine. All are naturally occurring substances. Glatiramer acetate has been approved by the Food and Drug Administration (FDA) in the US for being helpful in the reduction of relapse frequency for the disease multiple sclerosis.
L-glutamine helps in the production of the natural anti-oxidant glutathione, which has a crucial role in preventing cell damage since it is a powerful neuro-transmiter for central nervous system.
The approval of COPAXONE by the ministry followed favorable efficacy and results of a 52-week, open-label study. The study was conducted in Japan by the manufacturer in patients affected with relapsing-remitting MS.
There are many clinical studies done which has reinforced the efficacy of glutamine as a crucial nutrient for the prevention of various diseases such as cancer, Crohn’s disease and other tumor. The human body can produce L-glutamine itself, using L-glutamic acid as a neurotransmitter, but the deficiency can lead to the development of tumors. Many L-glutamic acid supplements are available in the nutritional market which can be taken after proper clinical recommendation. There are many reports in the market which tracks the demand of the compound L-glutamic acid along with offering industry insights into the current and future market trends. A recent report added by Prof Research Reports titled “Global and Chinese L-Glutamic Acid (CAS 56-86-0) Industry, 2009-2019 Market Research Report” offers a detailed insights into the changing market dynamics in terms of key drivers and restraints, market profile of key market players along with detailed segmentation and forecast.